



OLIGOMERIX, Inc.

Unleashing the Potential of Tau Oligomer Inhibition™

Oligomerix, Inc to Participate in the NIH Innovation Zone at the 2019 BIO International Convention

NEW YORK - May 30, 2019 - Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the company is one of the select group of NIH SBIR awardees chosen to participate in the NIH Innovation Zone at the 2019 BIO International Convention. The conference will take place June 3-6, 2019 at the Philadelphia Convention Center.

Details are as follows:

Exhibit at NIH Innovation Zone

Dates: June 4-6, 2019

Location: Booth 4270, Kiosk IZ-29

Company Presentation

Date: June 3, 2019

Time: 3:45 pm

Location: BIO Business Forum, Theater 3

"We are grateful that the NIH selected Oligomerix to participate in the Innovation Zone at BIO and are excited to be one of the few companies chosen for a presentation," said James Moe, Ph.D., MBA, President and CEO of Oligomerix. "We look forward to advancing our partnering discussions and explaining our core technology's unique approach to targeting tau oligomers."

Through the Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program, the National Institutes of Health (NIH) has funded many promising technologies and is committed to assisting its grantees/awardees further on their path to commercialization. This year NIH partnered with BIO to provide select SBIR/STTR awardees with premier visibility at the BIO International Convention, providing each company with access to business development executives from around the globe, as well as investors.

The upcoming 2019 BIO International Convention (June 3-6 in Philadelphia, PA) features more than 16,000 attendees in the life science and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. The event offers opportunities to partner, learn, and network with global biotech and pharma leaders.

This year, there will be a high profile, 6,300 square foot area of the Exhibition floor branded as the Innovation Zone, a turn-key exhibit space dedicated to showcasing 80 NIH SBIR/STTR awardees.

About Oligomerix, Inc.

Oligomerix is an early-stage biotechnology company focused on discovering and developing novel, small-molecule tau oligomer inhibitors for Alzheimer's disease (AD) and related neurodegenerative diseases with tau pathology. Oligomerix' drug discovery platform has identified a pipeline of novel, central nervous system (CNS), small molecule lead compounds for neurodegenerative diseases such as AD. The leads were designed to inhibit tau oligomer formation at the beginning of the aggregation process and in vivo proof-of-concept has been achieved in an animal model best representing tau aggregation in AD. The company's lead program targeting AD has initiated IND-enabling studies. The NYC based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine and has received considerable support from the National Institute on Aging of the National Institute of Health (NIH). Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs. For more information about Oligomerix, please visit www.oligomerix.com.

Company Contact:

Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

James Moe, Ph.D., MBA
President and CEO
212-568-0365
jmoe@oligomerix.com

Media Contact:

Michelle Linn
Bioscribe
774-696-3803
michelle@bioscribe.com